Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 2:2020:4263079.
doi: 10.1155/2020/4263079. eCollection 2020.

Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

Affiliations
Review

Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

Wenping Gong et al. Biomed Res Int. .

Abstract

Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis, is one of the top ten infectious diseases worldwide, and is the leading cause of morbidity from a single infectious agent. M. tuberculosis can cause infection in several species of animals in addition to humans as the natural hosts. Although animal models of TB disease cannot completely simulate the occurrence and development of human TB, they play an important role in studying the pathogenesis, immune responses, and pathological changes as well as for vaccine research. This review summarizes the commonly employed animal models, including mouse, guinea pig, rabbit, rat, goat, cattle, and nonhuman primates, and their characteristics as used in TB vaccine research, and provides a basis for selecting appropriate animal models according to specific research needs. Furthermore, some of the newest animal models used for TB vaccine research (such as humanized animal models, zebrafish, Drosophila, and amoeba) are introduced, and their characteristics and research progress are discussed.

PubMed Disclaimer

Conflict of interest statement

The authors do not have commercial or other associations that might pose a conflict of interest.

Figures

Figure 1
Figure 1
Statistical map of the utilization of different animal models in preclinical studies of TB vaccines. The source of the publications was an NCBI (National Center for Biotechnology Information) PubMed search using the keywords (vaccine AND tuberculosis AND ten categories shown in figure). The statistics were plotted using an open source graph visualization and manipulation software termed Gehpi. Each study is represented by a blue dot, and each animal model is represented by a circle of different color. The circle size represents the frequency of use of the animal model.
Figure 2
Figure 2
Tubercles of spleen or lung collected from guinea pigs or mice infected with M. tuberculosis H37Rv strain. BALB/c mice or guinea pigs were challenged with M. tuberculosis H37Rv strain (2 × 105 CFUs or 5 × 103 CFUs) to construct M. tuberculosis infected mouse or guinea pig TB model, respectively. After 3 days or 1 week, mice or guinea pigs were immunized intramuscularly three times at 2-weeks intervals with M. tuberculosis Ag85A/B chimeric DNA vaccine (vaccine group) or normal saline (negative control), respectively. Three weeks after last immunization, the mice or guinea pigs were sacrificed and their spleen and lung were collected to observe pathological lesions.

Similar articles

Cited by

References

    1. WHO. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. pp. 1–243.
    1. Sharma S. K., Katoch K., Sarin R., et al. Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Scientific Reports. 2017;7(1):p. 3354. doi: 10.1038/s41598-017-03514-1. - DOI - PMC - PubMed
    1. von Reyn C. F., Mtei L., Arbeit R. D., et al. Prevention of tuberculosis in Bacille Calmette–Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2010;24(5):675–685. doi: 10.1097/QAD.0b013e3283350f1b. - DOI - PMC - PubMed
    1. Gong W., Liang Y., Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Human Vaccines & Immunotherapeutics. 2018;14(7):1697–1716. doi: 10.1080/21645515.2018.1458806. - DOI - PMC - PubMed
    1. Tanner R., McShane H. Replacing, reducing and refining the use of animals in tuberculosis vaccine research. ALTEX. 2017;34(1):157–166. doi: 10.14573/altex.1607281. - DOI - PubMed

Substances

LinkOut - more resources